摘要
目的探讨经尿道双极等离子前列腺电切术(PKRP)与前列腺剜除术(PKEP)治疗高危良性前列腺增生的临床效果。方法将2016年1月~2018年12月因高危良性前列腺增生于我院行手术治疗的90例患者纳入研究,依据随机数字表法分为对照组与观察组,各45例。对照组采用PKRP术,观察组采用PKEP术。比较两组的手术一般情况及手术并发症情况,观察两组治疗前后的最大尿流率(Qmax)、国际前列腺症状评分(IPSS)改善情况。结果观察组的前列腺切除重量大于对照组,留置导尿管时间、手术时间均短于对照组,术中出血量少于对照组,差异有统计学意义(P<0.05);两组治疗后的Qmax、IPSS评分比较,差异无统计学意义(P>0.05);观察组的并发症总发生率为17.78%,低于对照组的37.78%,差异有统计学意义(P<0.05)。结论经尿道前列腺剜除术较电切术而言具有创伤小、恢复快、并发症少的优势,值得推广。
Objective To investigate the clinical effect of transurethral plasmakinetic resection of prostate (PKRP) and transurethral plasmakinetic enucleation of prostate (PKEP) in the treatment of high risk benign prostatic hyperplasia. Methods A total of 90 patients with high-risk benign prostatic hyperplasia in our hospital from January 2016 to December 2018 were enrolled in the study, according to the random number table method, the patients were divided into the control group and the observation group, 45 cases in each group. The control group was treated with PKRP, while the observation group was treated with PKEP. The general conditions of operation and complications were compared between the two groups. The improvement of maximum urinary flow rate (Qmax) and the international prostate symptom score (IPSS) before and after treatment was observed. Results The weight of prostatectomy in the observation group was greater than that in the control group, the time of indwelling catheter and the operation time in the observation group was shorter than that in the control group, the amount of bleeding during operation in the observation group was less than that in the control group, the difference was statistically significant (P<0.05). After treatment, there was no significant difference in Qmax and IPSS score between the two groups (P>0.05). The complication rate of the observation group was 17.78%, which was lower than that of the control group (37.78%) the difference was statistically significant (P<0.05). Conclusion PKEP has the advantages of less trauma, quicker recovery and fewer complications than transurethral resection of the prostate, and is worthy of promotion.
作者
叶韬
李成文
高加胜
李志坚
YE Tao;LI Cheng-wen;GAO Jia-sheng;LI Zhi-jian(Department of Urology,the First People′s Hospital of Jiujiang City in Jiangxi Province,Jiujiang 332000,China)
出处
《中国当代医药》
2019年第28期104-107,共4页
China Modern Medicine
作者简介
叶韬(1983-),男,湖南株洲人,硕士,主治医师,主要从事泌尿外科疾病的临床微创治疗工作.
